Key result
Cardiac resynchronization therapy improves ventricular function, physical performance, and quality of life in patients with end-stage heart failure, and may serve as a bridge to heart transplantation.
Why the study?
Heart failure frequently progresses to end-stage disease refractory to medical therapy, prompting a review of state-of-the-art developments, advances, and unresolved issues regarding cardiac resynchronization therapy.
Does cardiac resynchronization therapy improve outcomes in patients with end-stage heart failure?
Does cardiac resynchronization therapy improve outcomes in patients with end-stage heart failure?
Cardiac resynchronization therapy improves ventricular function and quality of life in end-stage heart failure, serving as an important bridge to heart transplantation.
May support CRT consideration as bridge to transplant in end-stage HF; leaves open need for randomized confirmation.
Heart failure (HF) is a common condition, and its overall prevalence is constantly growing. HF ultimately progresses to end-stage disease that is refractory to optimal medical therapy and requires implantable devices or heart transplant. In recent years, cardiac resynchronization therapy (CRT) has been generally accepted in patients with NYHA class III or IV, reduced left ventricular ejection fraction (less than 35%), and the wide QRS complex (>120 msec). CRT improves the efficacy of heart ventricle function and, as a result, physical performance and quality of life. Reverse cardiac remodeling occurs at a pathophysiological level that improves systolic function. Patients with end-stage HF who are on the heart transplant list are a specific group in whom CRT is considered a “bridge” to surgery. This review paper discusses state-of-the-art, advances, and unresolved issues in this area. KEYWORDS: cardiac resynchronization therapy, heart failure, left ventricular remodeling, ejection fraction, heart transplant. FOR CITATION: Shumakov D.V., Zybin D.I., Popov M.A. et al. Resynchronization therapy in end-stage heart failure. Russian Medical Inquiry. 2021;5(4):206–211 (in Russ.). DOI: 10.32364/2587-6821-2021-5-4-206-211.
No takes yet. Share an insight, caveat, or question.
Shumakov et al. (2021) conducted a review in End-stage heart failure. Cardiac resynchronization therapy (CRT) vs. Optimal medical therapy was evaluated. Cardiac resynchronization therapy improves ventricular function, physical performance, and quality of life in patients with end-stage heart failure, and may serve as a bridge to heart transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: